EUVIMEDEUVIMED entdecken
Crossref

Depression scores change significantly after omalizumab treatment in patients with chronic spontaneous urticaria

Pelin Kuteyla Can, Piril Etikan, Ece Nur Degirmentepe, Emek Kocaturk

Asian Pacific Journal of Allergy and Immunology · 2024

DOI: 10.12932/ap-180920-0965 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Asian Pacific Journal of Allergy and Immunology, 2024. Verfasst von Pelin Kuteyla Can und 3 weiteren Autor:innen. Beteiligte Einrichtung: Medicalpark Maltepe Hospital; Dermatology and Venerology, Istanbul, Turkey. Hauptthemen laut MEDLINE: Omalizumab, Chronic Urticaria, Depression, Anti-Allergic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Chronic spontaneous urticaria (CSU) is frequently associated with psychiatric comorbidities. OBJECTIVE: We aimed to determine if depressive symptoms were present in CSU patients who received omalizumab and if depression scores got better with omalizumab treatment and whether the presence of depressive symptoms impaired treatment responses. METHODS: CSU patients who received at least three injections of omalizumab were included in the study. Changes in Urticaria Activity Score (UAS), Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL), Beck Depression Inventory (Beck-D) and Urticaria Control Test (UCT) scores were compared before and after treatment. RESULTS: From 49 patients, 20 (40.8%) had depressive symptoms at baseline. After treatment, UAS7, CU-Q2oL, Beck-D scores decreased and UCT-scores increased significantly (p < 0.001, for all). UCT scores were lower at baseline and at 3rd month following treatment in patients with depressive symptoms compared to patients without (baseline median (interquartile range-IQR) 2.5 (1-5) vs 5 (2.5-6.5); p = 0.04 and 3rd month 12 (9-13) vs 14 (12-16); p = 0.006, respectively). Omalizumab non-responders had higher baseline Beck-D-scores [18.5 (15.2-22) vs 12 (6-22.5); p = 0.031]. The number of omalizumab non-responders were significantly higher among patients with depressive symptoms compared to patients without. (40% vs 13.8%; p = 0.048). Only 6 patients scored as having depressive symptoms after treatment; of these 6 patients only one was an omalizumab responder. CONCLUSIONS: Omalizumab not only provides symptom control for urticaria but also improves psychological conditions of the patients. Coexistent psychiatric comorbidities should be taken into account in CSU patients since these conditions might impair treatment response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OmalizumabChronic UrticariaDepressionAnti-Allergic AgentsQuality of LifeHumansFemaleMaleAdultMiddle AgedTreatment OutcomeSurveys and Questionnaires

Substanzen

OmalizumabAnti-Allergic Agents

Autor:innen und Institutionen

  • Medicalpark Maltepe Hospital; Dermatology and Venerology, Istanbul, Turkey.
  • Okmeydani Training and Research Hospital; Dermatology and Venerology, Istanbul, Turkey.
  • Koç University School of Medicine; Department of Dermatology, Istanbul, Turkey.

Zitieren

APA

Can, P. K., Etikan, P., Degirmentepe, E. N., & Kocaturk, E. (2024). Depression scores change significantly after omalizumab treatment in patients with chronic spontaneous urticaria. Asian Pacific Journal of Allergy and Immunology. https://doi.org/10.12932/ap-180920-0965

Vancouver

Can PK, Etikan P, Degirmentepe EN, Kocaturk E. Depression scores change significantly after omalizumab treatment in patients with chronic spontaneous urticaria. Asian Pacific Journal of Allergy and Immunology. 2024. doi:10.12932/ap-180920-0965

BibTeX
@article{Can2024,
  author = {Can, Pelin Kuteyla and Etikan, Piril and Degirmentepe, Ece Nur and Kocaturk, Emek},
  title = {Depression scores change significantly after omalizumab treatment in patients with chronic spontaneous urticaria},
  journal = {Asian Pacific Journal of Allergy and Immunology},
  year = {2024},
  doi = {10.12932/ap-180920-0965}
}
Kostenlos starten →